𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Acute tumor lysis syndrome secondary to hydroxycarbamide in chronic myelomonocytic leukemia

✍ Scribed by Zaher K. Otrock; Ali T. Taher; Rami A.R. Mahfouz; Jawad A. Makarem; Ali I. Shamseddine

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
235 KB
Volume
81
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Tumor lysis syndrome in a case of chroni
Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids
✍ Coutinho, Anelisa K.; Santos, Marcelo de O.; Pinczowski, HΓ©lio; Feher, Olavo; de πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 164 KB πŸ‘ 2 views

To the Editor: Schwachman's syndrome, a familial disease transmitted as an autosomal-recessive trait, is characterized by moderate chronic neutropenia, marked marrow hypocellularity, occasional thrombocytopenia and anemia, metaphyseal dysostosis of tubular bones, pancreatic fatty infiltration, and a

Tumor lysis syndrome occurring after the
Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
✍ Yang, Honghao; Rosove, Michael H.; Figlin, Robert A. πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 27 KB πŸ‘ 1 views

Rituximab, an anti-CD20 antibody, has been recently approved for the treatment of lowgrade or follicular non-Hodgkin's lymphoma (NHL). Because of its relatively benign side effect profile, it has been considered a nontoxic alternative to chemotherapy. Recently, however, tumor lysis syndrome (TLS) re